Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
复制标题
DOI：
10.1161/01.cir.96.12.4219
复制
发表时间：
1997-12
期刊：
影响因子：
37.8
通讯作者：
Shih-Jen Hwang;C. Ballantyne;A. Sharrett;L. Smith;C. Davis;A. Gotto;E. Boerwinkle
中科院分区：
文献类型：
--
作者：
Shih-Jen Hwang;C. Ballantyne;A. Sharrett;L. Smith;C. Davis;A. Gotto;E. Boerwinkle
背景：循环白细胞在动脉粥样硬化部位的募集是通过一系列黏附分子来调节的。这些黏附分子的循环形式的功能尚不清楚，但它们的水平可能作为亚临床冠心病(CHD)的分子标志物。方法与结果通过检测循环血管细胞黏附分子-1(VCAM-1)、血管内皮细胞-白细胞黏附分子-1(E-选择素)和细胞间黏附分子-1(ICAM-1)作为动脉粥样硬化的分子标志物和冠心病发生的预测指标的能力，我们研究了204例冠心病发病患者、272例颈动脉粥样硬化(CAA)患者和316例对照组。冠心病组、冠心病组和对照组之间的VCAM-1水平无显著差异。冠心病组和冠心病组E-选择素和细胞间黏附分子-1水平分别为288.7和283.6，均高于对照组(分别为32.8和244.2)，但两组间差异无统计学意义。Logistic回归分析结果表明，ICAM-1和E-选择素与CHD和CAA的关系独立于其他已知的冠心病危险因素，且在最高四分位数处最为显著。ICAM-1水平最高四分位数与最低四分位数相比，发生冠心病和CAA的几率分别为5.53(95%CI，2.51~12.21)和2.64(95%CI，1.40~5.01)。E-选择素水平位于最高四分位数与最低四分位数者发生CAA的优势比为2.03(95%CI，1.14~3.62)。结论血浆ICAM-1和E-选择素水平可作为动脉粥样硬化和冠心病发生发展的分子标志物。
BACKGROUND Recruitment of circulating leukocytes at sites of atherosclerosis is mediated through a family of adhesion molecules. The function of circulating forms of these adhesion molecules remains unknown, but their levels may serve as molecular markers of subclinical coronary heart disease (CHD). METHODS AND RESULTS To determine the ability of circulating vascular cell adhesion molecule-1 (VCAM-1), endothelial-leukocyte adhesion molecule-1 (E-selectin), and intercellular adhesion molecule-1 (ICAM-1) to serve as molecular markers of atherosclerosis and predictors of incident CHD, we studied 204 patients with incident CHD, 272 patients with carotid artery atherosclerosis (CAA), and 316 control subjects from the large, biracial Atherosclerosis Risk In Communities (ARIC) study. Levels of VCAM-1 were not significantly different among the patients with incident CHD, those with CAA, and control subjects. Higher levels of E-selectin and ICAM-1 were observed for the patients with CHD (means [ng/mL]: E-selectin, 38.4; ICAM-1, 288.7) and those with CAA (E-selectin, 41.5; ICAM-1, 283.6) compared with the control subjects (E-selectin, 32.8; ICAM-1, 244.2), but the distributions were not notably different between the patients with CHD and CAA. Results of logistic regression analyses indicated that the relationship of ICAM-1 and E-selectin with CHD and CAA was independent of other known CHD risk factors and was most pronounced in the highest quartile. The odds of CHD and CAA were 5.53 (95% CI, 2.51-12.21) and 2.64 (95% CI, 1.40-5.01), respectively, for those with levels of ICAM-1 in the highest quartile compared with those in the lowest quartile. Odds of CAA were 2.03 (95% CI, 1.14-3.62) for those with levels of E-selectin in the highest quartile compared with those in the lowest quartile. CONCLUSIONS These data indicate that plasma levels of ICAM-1 and E-selectin may serve as molecular markers for atherosclerosis and the development of CHD.